[1]赵伟河,牛振霞,郎金飞,等.益肾补脾汤治疗糖尿病肾脏病Ⅳ期疗效观察[J].新乡医学院学报,2023,40(4):329-332.[doi:10.7683/xxyxyxb.2023.04.006]
　ZHAO Weihe,NIU Zhenxia,LANG Jinfei,et al.Clinical efficacy of Yishen Bupi decoction in the treatment of stage IV diabetic kidney disease[J].Journal of Xinxiang Medical University,2023,40(4):329-332.[doi:10.7683/xxyxyxb.2023.04.006]
点击复制

益肾补脾汤治疗糖尿病肾脏病Ⅳ期疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
40卷
期数:
2023年4
页码:
329-332
栏目:
临床研究
出版日期:
2023-04-05

文章信息/Info

Title:
Clinical efficacy of Yishen Bupi decoction in the treatment of stage IV diabetic kidney disease
作者:
赵伟河; 牛振霞; 郎金飞; 耿雪; 郭若楚; 赵磊
（河南省荣军医院内分泌科，河南　新乡　453000）
Author(s):
ZHAO Weihe; NIU Zhenxia; LANG Jinfei; GENG Xue; GUO Ruochu; ZHAO Lei
(Department of Endocrinology,Henan Rongjun Hospital,Xinxiang 453000,Henan Province,China)
关键词:
糖尿病肾脏病; 益肾补脾汤; 肾功能; 尿蛋白
Keywords:
diabetic kidney disease; Yishen Bupi decoction; renal function; urine protein
分类号:
R587.2；R692.5
DOI:
10.7683/xxyxyxb.2023.04.006
文献标志码:
A
摘要:
目的观察益肾补脾汤治疗糖尿病肾脏病Ⅳ期的临床疗效。方法选择河南省荣军医院2021年7月至2022年6月收治的2型糖尿病肾脏病Ⅳ期患者60例为研究对象，将患者随机分为观察组和对照组，每组30例。2组患者均给予降血糖、降血压、调血脂等常规西药治疗，观察组患者在此基础上加用中药益气补脾汤治疗1个月。比较2组患者的临床疗效和证候疗效。分别于治疗前、治疗1个月时采集2组患者空腹静脉血3 mL，采用全自动生物化学分析仪检测血肌酐、血尿素氮水平；同时收集患者的尿液5 mL，采用免疫比浊法检测尿微量白蛋白、肌酐水平，并计算尿微量白蛋白/肌酐比值。结果观察组和对照组患者临床疗效的总有效率分别为76.7%(23/30)、40.0%(12/30)，证候疗效的总有效率分别为86.7%（26/30）、53.3%（16/30）。观察组患者的临床疗效及证候疗效的总有效率均显著高于对照组（χ2=8.297、7.937,P<0.05）。治疗前2组患者的血肌酐、尿素氮、尿微量白蛋白/肌酐比值比较差异均无统计学意义（P>0.05）。治疗后，2组患者的血肌酐、尿素氮、尿微量白蛋白/肌酐比值均显著低于治疗前（P<0.05）。治疗后，观察组患者的血肌酐、尿素氮、尿微量白蛋白/肌酐比值均显著低于对照组（P<0.05）。结论益肾补脾汤治疗糖尿病肾脏病Ⅳ期疗效确切，其与西医常规治疗联合可有效提高患者的临床疗效，改善肾功能。
Abstract:
ObjectiveTo observe the clinical efficacy of Yishen Bupi decoction in the treatment of stage IV diabetic kidney disease.MethodsSixty patients with type 2 diabetic kidney disease stage IV admitted to Henan Rongjun Hospital from July 2021 to June 2022 were selected as research subjects.The patients were randomly divided into observation group and control group,with 30 cases in each group.All patients were given conventional western medicine treatment such as hypoglycemia,hypotension and lipid regulation;based on this,the patients in the observation group was treated with Yishen Bupi decoction for one month.The clinical efficacy and syndrome efficacy of patients were compared between the two groups.Before treatment and one month after treatment,3 mL of fasting venous blood was collected from patients in the two groups,and the levels of serum creatinine and blood urea nitrogen were measured by automatic biochemical analyzer;at the same time,5 mL urine of the patients was collected,and the levels of urinary microalbumin and creatinine were detected by immunoturbidimetry,then the ratio of microalbumin/creatinine was calculated.ResultsThe total effective rates of clinical efficacy of patients in the observation group and the control group were 76.7% (23/30) and 40.0% (12/30),respectively,and the total effective rates of syndrome efficacy were 86.7% (26/30) and 53.3% (16/30),respectively;the effective rates of clinical efficacy and syndrome efficacy of patients in the observation group were significantly higher than those in the control group (χ2=8.297,7.937;P<0.05).There was no significant difference in blood creatinine,urea nitrogen and urinary microalbumin/creatinine ratio of patients between the two groups before treatment (P>0.05).After treatment,the blood creatinine,urea nitrogen and urinary microalbumin/creatinine ratio of patients were significantly lower than those before treatment in the two groups (P<0.05).After treatment,the blood creatinine,urea nitrogen and urinary microalbumin/creatinine ratio of patients in the observation group were significantly lower than those in the control group (P<0.05).ConclusionThe efficacy of Yishen Bupi decoction is effective in the treatment of DKD stage IV,and its combination with conventional western medicine treatment can effectively improve the clinical efficacy and renal function of patients.

参考文献/References:

［1］　ZHANG X X,KONG J,YUN K.Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China：a meta-analysis of observational studies［J］.J Diabetes Res,2020,2020:2315607.
［2］　王宓，左力.糖尿病肾脏病诊治专家共识解读［J］.临床内科杂志，2020，37（9）：675-678.
WANG M,ZUO L.Understanding of expert consensus on diagnosis and treatment of diabetes nephropathy［J］.J Clin Intern Med，2020，37（9）：675-678.
［3］　中华医学会糖尿病分会微血管并发症学组.中国糖尿病肾脏病防治指南（2021年版）［J］.中华糖尿病杂志,2021,13(8):762-784.
MICROVASCULAR COMPLICATIONS GROUP,CHINESE DIABETES SOCIETY.Clinical guideline for the prevention and treatment of diabetic kidney disease in China (2021 edition) ［J］.Chin J Diabetes Mellitus,2021,13(8):762-784.
［4］　曹雯，喻嵘，王琦威，等.中西医结合治疗糖尿病肾脏病随机对照试验的Meta分析［J］.中华中医药学刊，2019，35（4）：112-114.
CAO W,YU R,WANG Q W,et al.Meta analysis of randomized controlled trials of integrated traditional Chinese and western medicine in the treatment of diabetes nephropathy［J］.Chin J Tradit Chin Med,2019，35（4）：112-114.
［5］　AMERICAN DIABETES ASSOCIATION.Microvascular complications and foot care［J］.Diabetes Care,2015,38 Suppl:S58-S66.
［6］　中华中医药学会肾病分会.糖尿病肾病诊断、辨证分型及疗效评定标准［J］.上海中医药杂志,2007,41(7):7-8.
CHINESE SOCIETY OF TRADITIONAL CHINESE MEDICINE KIDNEY DISEASE BRANCH.Criteria for diagnosis,syndrome differentiation and efficacy evaluation of diabetes nephropathy［J］.Shanghai J Tradit Chin Med,2007,41(7):7-8.
［7］　中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）［J］.中华糖尿病杂志,2021,13(4):315-409.
CHINESE DIABETES SOCIETY.Chinese guidelines for the prevention and treatment of type 2 diabetes(version 2020) ［J］.Chin J Diabetes Mellitus,2021,13(4):315-409.
［8］　林兰,倪青.2型糖尿病“三型辩证”的理论与实践［J］.科学中国人,2011(9):78-81.
LIN L,NI Q.The theory and practice of "three type dialectics" in type 2 diabetes［J］.Sci Chin,2011(9):78-81.
［9］　仝小林.糖尿病中医认识及研究进展述评［J］.北京中医药,2016,35(6):509-512.
TONG X L.Review on the cognition and research progress of diabetes in traditional Chinese medicine［J］.Beijing J Tradit Chin Med,2016,35(6):509-512.
［10］　中华中医药学会.中医糖尿病临床诊疗指南［M］.北京：中国中医药出版社,2020:23-31.
CHINESE SOCIETY OF TRADITIONAL CHINESE MEDICINE.Guide to clinical diagnosis and treatment of diabetes in traditional Chinese Medicine［M］.Beijing:China Traditional Chinese medicine Press,2020:23-31.
［11］　赵雯红,张江华,孙姗姗,等.IV期糖尿病肾脏病患者中医辩证分型与“血瘀”状态相关实验室指标的规律性研究［J］.河北中医,2019,41(3):337-341,371.
ZHAO W H,ZHANG J H,SUN S S,et al.Study on the regularity of laboratory indicators related to TCM syndrome differentiation and typing and "blood stasis" status in patients with stage Ⅳ diabetic nephropathy［J］.Hebei J TCM,2019,41(3):337-341,371.
［12］　王嘉，谷鑫，吴承玉.从“病位、病性”论糖尿病肾脏病的藏象辩证思路［J］中国临床研究,2019,32(11):1574-1576.
WANG J,GU X,WU C Y.Visceral differentiation of diabetic nephropathy from "disease location" and "disease nature"［J］.Chin J Clin Res,2019,32(11):1574-1576.
［13］　池杨峰，刘爽，王浩，等.黄芪汤对糖尿病肾脏病Ⅲ期患者蛋白尿及相关炎症因子的影响［J］.中国中西医结合肾病杂志,2020,21(4):305-308.
CHI Y F,LIU S,WANG H,et al.Effect of Huangqi Decoction on proteinuria and related inflammatory factors expression of patients with diabetic kidney disease Ⅲ［J］.CJITWN,2020,21(4):305-308.
［14］　王永军，贺延法，石良静，等.益气养阴通络方联合常规西药治疗对早期糖尿病肾脏病患者肾功能和炎症因子的影响［J］.河北中医,2019,41(6):874-879,885.
WANG Y J,HE Y F,SHI L J,et al.Effect of Yiqi Yangyin Tongluo recipe combined with conventional western medicine on renal function and inflammatory factor in early diabetic nephropathy patients［J］.Hebei J TCM,2019,41(6):874-879,885.
［15］　郁越，孙伟.中西医结合方案治疗2型糖尿病肾脏病Ⅳ期60例临床观察［J］.中国中西医结合肾病杂志,2019,20(6):540-541.
YU Y,SUN W.Clinical observation on 60 cases of type 2 diabetes nephropathy stage Ⅳ treated by integrated traditional Chinese and western medicine［J］.CJITWN,2019,20(6):540-541.
［16］　赵能江，代春美，孙文杰，等.《中国2型糖尿病防治指南（2020年版）》糖尿病的中医药治疗部分解读［J］.中华糖尿病杂志,2021,13(4):309-311.
ZHAO N J,DAI C M,SUN W J,et al.The interpretation of treatment of diabetes with traditional Chinese medicine in guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)［J］.Chin J Diabetes Mellitus,2021,13(4):309-311.
［17］　中国医师协会中西医结合医师分会内分泌与代谢病专业委员会.糖尿病前期病症结合诊疗指南［J］.世界中医药,2021,16(4):533-538.
ENDOCRINE AND METABOLIC DISEASES PROFESSIONAL COMMITTEE OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE BRANCH OF CHINESE MEDICAL ASSOCIATION.Guidelines for the diagnosis and treatment of prediabetes combined with disease and syndrome［J］.World Chin Med,2021,16(4):533-538.

更新日期/Last Update: 2023-04-05